Member Info for Drillspark

There’s only one thing predictable…..the utter dross that spews from your posts……give everyone a break…go do one!

As stated in the Sept RNS……
Various stakeholders, including potential service providers, and our Master Distribution Partner also visited the site this season. These visits assist planning and progress towards achieving a robust and de-risked case for Dundas. We expect to provide a further and fuller update in Q4 2022.
Let’s hope they stick to there word.

MMS are not even trying to disguise there manipulation….wonder how big the backhanders from Brontë are to get them out…….

Would be fairly sure that the Nomad has forced AVCTs hand with that RNS…the bit that’s laughable is there are no signs of the Nomad stepping in when the SP is getting trashed on the strength of a rumour suggested by the toothless Greek olive farmer……AIM really is a fkn joke…

https://t.co/bttatFG2cK
Get producing lithium..it’s a licence to print money……come on Afritin , get your finger out!

Had a look in to this Moram …….it’s a single investor….read the following….
Who is MORAM? – Background


I am Carlos Mora, an industrial engineer specialised in the energy sector. I worked for more than five years as a management & Strategy Consultant at Indra Business Consulting & NTT. During that period, I was involved in M&A and strategy projects for multinationals such as Enel, Naturgy, Telenor… However, finances are my passion. Consequently, I studied finance and economics by myself after university. I took courses in the Wharton University and London School of Economics. Moreover, I read books of Benjamin Graham and Peter Lynch. I have been analysing companies since 2014. In 2016 I started to manage the portfolio of some family and friends. Since 2018, I help other people to manage their portfolios.

Good positive message from the new man at the helm…..more than anything to restore investor faith…..best move was getting rid of the space cadet Hockey and his COO, who looks like he was miles out of his depth..

New management need to have good long look at Petrofacs involvement in this sh*t show…
As quoted
The planning phase includes detailed well design, risk assessment and management of well-related regulatory requirements. During the execution phase Petrofac will manage well engineering, procurement and logistics, assure well construction and integrity, and provide onshore and offshore personnel to support the drilling campaign.

Amazes me the company cannot see the need for an operations update, good or bad to clear the waters, management (Hockey) are very good at slapping themselves on the back at how well they have done but are totally inept when things don’t go so well, which is far too often for it to be bad luck, CEO needs to take the heat and go….

Wooster….if you read the presentation on IOG website, it states
Southwark A2 (East) production well drilled in Q2
Southwark A1 (West) well drilling resumed in early Q3 – progress hindered by fluid losses in Bunter Sandstone Formation but well plan continues to be executed.
Add to the fact your fear mongering has no substance, no information as to depth they started loosing mud, have they kicked off to the horizontal section, no one knows , so to start implying reservoir damage etc is out of order…..ulterior motives me thinks!

More disappointed about the “significant delays” with the drilling at Southwark…..what now , not in production before the winter…

SpArmada…your post started Kistos are “debt free”….excuse my French but total bulls**t, and further you knew it with your latest post, because they had £6.3million in cash doesn’t mean Yada…….doubts prevail about your intentions.

SPArmada =troll, at least get your facts about Kistos correct, did the £150million Nordic bond just disappear ?….total liabilities of £286 million , an operating loss of £62million (end of 21), and the liabilities have just gone up after the 20% Total deal…..so please , go do one…

SPArmada…I didn’t suggest any problems!
“ Putford Jaguar has been close to Blythe for more than 1 day now, could they be working on the final repair of the chemical injection fault? Maybe another shut down due to mechanical issues? ”
I suggest you did…

Kistos market cap £400m , IOG £16i8m, compare production numbers, reserves, levels of debt, etc can’t find an OPEX issuesd anywhere for KIST…….but do your own research and you will find there is a huge disconnect between the companies, IOG is absurdly cheap, with a big increase of production by the end of the year(all going to plan) makes the price presently a bargain…….fill the boots time..

The good news is that there efforts to continue spreading FU&D are getting more and more ridiculous and in the process making themselves look even bigger t*ts than they do already.

Wress the King Plum is on to the next name on his Twitter list….Babblers Best Buys…

Not in chronological order.
1. They move therapeutics lock stock and barrel to London
2. They present a poster at AACR
3.They launch the next precision candidate AVA3996
4. They add significantly to the Scientific board and the services of a highly regarded Chief Scientific Officer.
5.They achieve FDA approval for clinical trials of AVA6000 in the USA.
All if not the majority of those items are due to the outcome and evidence of what they are seeing in the clinical trials, if this is not the case the Senior Management of Avacta’s reputations are shot …….it would not make any sense to do what they have done if AVA6000 was not performing as good or if not better than predicted.

Unfortunately the serial liar is still on Twitter, his username, or sorry one of his usernames has changed from cowrhehelldoiknow to alexcoombes

“ an experimental medicine combined with Atezolizumab, an immunotherapy drug administered intravenously which she continues to have every three weeks”

For Avacta’s Therapeutics division, the next few months in its new facilities are set to be busier than ever, with its lead AVA6000 FAP-activated drug technology now in phase 1 clinical trials. AVA6000 is a first-in-class FAP activated technology based on the pre|CISION™ platform, providing a masked form of doxorubicin with an improved safety profile, and enabling broader use in oncology – particularly in combinations with immuno-oncology drug agents.